Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I

Background: Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disease caused by a deficiency of the lysosomal enzyme α-L-iduronidase. Cardiac manifestations such as valvular heart disease are associated with poor prognosis. There have been only a few reports on the effect of long-te...

Full description

Bibliographic Details
Main Authors: Kenta Sugiura, Toru Kubo, Yuri Ochi, Yuichi Baba, Takayoshi Hirota, Naohito Yamasaki, Hiroaki Kitaoka
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Molecular Genetics and Metabolism Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2214426920301087
id doaj-df25cf6fd55843269fd3aeadfd072811
record_format Article
spelling doaj-df25cf6fd55843269fd3aeadfd0728112020-12-19T05:07:18ZengElsevierMolecular Genetics and Metabolism Reports2214-42692020-12-0125100662Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type IKenta Sugiura0Toru Kubo1Yuri Ochi2Yuichi Baba3Takayoshi Hirota4Naohito Yamasaki5Hiroaki Kitaoka6Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, JapanCorresponding author at: Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Oko-cho, Nankoku-shi, Kochi 783–8505, Japan.; Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, JapanDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Kochi, JapanBackground: Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disease caused by a deficiency of the lysosomal enzyme α-L-iduronidase. Cardiac manifestations such as valvular heart disease are associated with poor prognosis. There have been only a few reports on the effect of long-term enzyme replacement therapy (ERT) for adult patients with the attenuated form of MPS I (Scheie syndrome) and cardiac involvement. Methods: We retrospectively reviewed four adult patients of Scheie syndrome for which ERT was performed in our hospital. We investigated the findings of electrocardiography and echocardiography for the four patients performed before and 10 years after the initiation of ERT to evaluate the efficacy for ERT in Scheie syndrome. Results: The ages of the patients at the initiation of ERT ranged from 26 to 46 years. The mean follow-up period was 129 months (121 to 134 months). Two patients underwent valve replacement surgery before the initiation of ERT. One patient had gradual progressive aortic valve stenosis and mitral valve stenosis during the course of ERT, and double valve replacement was finally performed. The patient who had started ERT at the youngest age did not develop significant cardiovascular disease. Regarding clinical courses with ERT for a period of 10 years, all four patients survived and they showed relatively stable cardiac conditions although two patients developed sick sinus syndrome after the valvular surgery. Conclusions: Valvular disease in patients with Scheie syndrome occur at a young age. In a limited number of the four patients, ERT might contribute the stability of cardiac condition.http://www.sciencedirect.com/science/article/pii/S2214426920301087MucopolysaccharidosisScheie syndromeEnzyme replacement therapyAdultsValvular disease
collection DOAJ
language English
format Article
sources DOAJ
author Kenta Sugiura
Toru Kubo
Yuri Ochi
Yuichi Baba
Takayoshi Hirota
Naohito Yamasaki
Hiroaki Kitaoka
spellingShingle Kenta Sugiura
Toru Kubo
Yuri Ochi
Yuichi Baba
Takayoshi Hirota
Naohito Yamasaki
Hiroaki Kitaoka
Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
Molecular Genetics and Metabolism Reports
Mucopolysaccharidosis
Scheie syndrome
Enzyme replacement therapy
Adults
Valvular disease
author_facet Kenta Sugiura
Toru Kubo
Yuri Ochi
Yuichi Baba
Takayoshi Hirota
Naohito Yamasaki
Hiroaki Kitaoka
author_sort Kenta Sugiura
title Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
title_short Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
title_full Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
title_fullStr Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
title_full_unstemmed Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I
title_sort cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type i
publisher Elsevier
series Molecular Genetics and Metabolism Reports
issn 2214-4269
publishDate 2020-12-01
description Background: Mucopolysaccharidosis type I (MPS I) is a rare autosomal recessive disease caused by a deficiency of the lysosomal enzyme α-L-iduronidase. Cardiac manifestations such as valvular heart disease are associated with poor prognosis. There have been only a few reports on the effect of long-term enzyme replacement therapy (ERT) for adult patients with the attenuated form of MPS I (Scheie syndrome) and cardiac involvement. Methods: We retrospectively reviewed four adult patients of Scheie syndrome for which ERT was performed in our hospital. We investigated the findings of electrocardiography and echocardiography for the four patients performed before and 10 years after the initiation of ERT to evaluate the efficacy for ERT in Scheie syndrome. Results: The ages of the patients at the initiation of ERT ranged from 26 to 46 years. The mean follow-up period was 129 months (121 to 134 months). Two patients underwent valve replacement surgery before the initiation of ERT. One patient had gradual progressive aortic valve stenosis and mitral valve stenosis during the course of ERT, and double valve replacement was finally performed. The patient who had started ERT at the youngest age did not develop significant cardiovascular disease. Regarding clinical courses with ERT for a period of 10 years, all four patients survived and they showed relatively stable cardiac conditions although two patients developed sick sinus syndrome after the valvular surgery. Conclusions: Valvular disease in patients with Scheie syndrome occur at a young age. In a limited number of the four patients, ERT might contribute the stability of cardiac condition.
topic Mucopolysaccharidosis
Scheie syndrome
Enzyme replacement therapy
Adults
Valvular disease
url http://www.sciencedirect.com/science/article/pii/S2214426920301087
work_keys_str_mv AT kentasugiura cardiacmanifestationsandeffectsofenzymereplacementtherapyforover10yearsinadultswiththeattenuatedformofmucopolysaccharidosistypei
AT torukubo cardiacmanifestationsandeffectsofenzymereplacementtherapyforover10yearsinadultswiththeattenuatedformofmucopolysaccharidosistypei
AT yuriochi cardiacmanifestationsandeffectsofenzymereplacementtherapyforover10yearsinadultswiththeattenuatedformofmucopolysaccharidosistypei
AT yuichibaba cardiacmanifestationsandeffectsofenzymereplacementtherapyforover10yearsinadultswiththeattenuatedformofmucopolysaccharidosistypei
AT takayoshihirota cardiacmanifestationsandeffectsofenzymereplacementtherapyforover10yearsinadultswiththeattenuatedformofmucopolysaccharidosistypei
AT naohitoyamasaki cardiacmanifestationsandeffectsofenzymereplacementtherapyforover10yearsinadultswiththeattenuatedformofmucopolysaccharidosistypei
AT hiroakikitaoka cardiacmanifestationsandeffectsofenzymereplacementtherapyforover10yearsinadultswiththeattenuatedformofmucopolysaccharidosistypei
_version_ 1724377812555530240